Chinese Regulators Report Steady Progress In Promoting Innovation - DIA China Conference
This article was originally published in PharmAsia News
BEIJING - China's State FDA has made steady progress in meeting the challenges of drug supervision while at the same time encouraging innovation and ensuring safety, SFDA Deputy Commissioner Wu Zhen told executives and scientists during the second Drug Information Association China annual meeting in Beijing this week
You may also be interested in...
BEIJING - Just days away from widely expected regulatory approval for an A/H1N1 vaccine, the Beijing-based Sinovac Biotech is now virtually guaranteed to become the first producer in the world to market a defense to the swine flu pandemic
SHANGHAI - China's State FDA is planning to launch a drug master file system to establish better controls for active pharmaceutical ingredients and drug excipients
China Issues Fast-Track Registration Procedure For Drugs To Balance Innovation And Risk: SFDA Press Conference
SHANGHAI - China's State FDA issued regulations on a special approval procedure to accelerate the approval process for new drug applications, effective Jan. 7